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Parkinson’s disease, diabetic retinopathy, hyperoxia induced retinopathy, and neuronal
damage resulting from ischemia are among the notable neurodegenerative diseases in
which oxidative stress occurs shortly before the onset of neurodegeneration. A shared
feature of these diseases is the depletion of OXR1 (oxidation resistance 1) gene products
shortly before the onset of neurodegeneration. In animal models of these diseases,
restoration of OXR1 has been shown to reduce or eliminate the deleterious effects of
oxidative stress induced cell death, delay the onset of symptoms, and reduce overall
severity. Moreover, increasing OXR1 expression in cells further increases oxidative stress
resistance and delays onset of disease while showing no detectable side effects. Thus,
restoring or increasing OXR1 function shows promise as a therapeutic for multiple
neurodegenerative diseases. This review examines the role of OXR1 in oxidative stress
resistance and its impact on neurodegenerative diseases. We describe the potential
of OXR1 as a therapeutic in light of our current understanding of its function at the
cellular and molecular level and propose a possible cascade of molecular events linked
to OXR1’s regulatory functions.
Keywords: gene therapy, OXR1, oxidative stress resistance, reactive oxygen species, neurodegeneration, retinal
degeneration
INTRODUCTION
OXR1 is emerging as a key player in the pathology of neurodegenerative diseases. It was discovered
as a gene required for oxidative stress resistance in eukaryotes 20 years ago (Volkert et al., 2000),
but interest in OXR1 has expanded as its role in neurodegeneration has become more widely
recognized. Most recent discoveries of the key roles ofOXR1 began as investigations into the genetic
mechanisms behind specific neurodegenerative diseases. These studies led to the conclusion that
OXR1 prevents progression of neurodegeneration by reducing oxidative stress and the damage and
cell death that oxidative stress causes. In many of the diseases in which OXR1 plays a role, its mRNA
and protein levels decline shortly before the initiation of oxidative stress and neurodegeneration.
Restoration of OXR1 expression prevents or delays the onset of the pathology (Murray et al., 2013;
Puspita et al., 2017; Mo et al., 2019).
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OXR1 has been implicated in a growing list of
neurodegenerative diseases such as oxygen-induced retinopathy,
diabetic retinopathy, Parkinson’s disease, ischemia-induced
neuronal damage, and amyotrophic lateral sclerosis (ALS)
(Natoli et al., 2008a; Murray et al., 2013; Finelli et al., 2015; Liu
et al., 2015; Puspita et al., 2017; Jiang et al., 2019; Williamson
et al., 2019). OXR1’s ability to reduce oxidative stress and
neurodegeneration in multiple diseases strongly suggests that
it can be an effective therapeutic target. Increasing OXR1
expression has also been shown to delay Lupus-associated
induced kidney failure, which is associated with oxidative
stress (Li et al., 2014), suggesting OXR1 may have therapeutic
applications beyond treating neurodegenerative diseases.
The role of OXR1 in these diseases is multifaceted. One
of its major functions is to control the expression of genes
that alleviate oxidative stress by increasing cellular resistance to
reactive oxygen species (ROS) and the stress these molecules
cause the cell. Oxidative stress occurs when levels of ROS,
including hydroxyl radicals, superoxide, singlet oxygen, and
other reactive forms of oxygen, exceed the cell’s capacity to
detoxify and inactivate these molecules and the cell’s ability to
repair the damage they cause to lipids, proteins, and nucleic
acids. Oxidative stress has long been implicated as a factor
that contributes to the pathology of many neurodegenerative
diseases including Alzheimer’s disease, Parkinson’s disease, ALS,
‘Huntington’s disease, Down’s syndrome, and multiple sclerosis
(Butterfield, 2006; Melo et al., 2011; Butterfield et al., 2012;
Kim et al., 2015; Ohl et al., 2016). Whether OXR1 plays
a role in all of these neurodegenerative diseases remains
to be determined.
Discovery and Demonstration That OXR1
Is Required for Oxidative Stress
Resistance
OXR1 was discovered in a search for human genes that could
prevent or repair spontaneous oxidative damage in an E. coli
strain engineered to report the level of oxidative mutagenesis
(Volkert et al., 2000, 2008; Elliott and Volkert, 2004). Further
studies of the yeast OXR1 homolog confirmed its requirement
for oxidative stress resistance in eukaryotes (Elliott and Volkert,
2004). The ability of the human homolog to restore oxidative
stress resistance to a yeast oxr1 deletion strain suggested its
function in stress resistance is conserved among the eukaryotic
OXR1 proteins (Elliott and Volkert, 2004). This conservation
of function has been substantiated in a number of studies of
invertebrates including mosquitos, Drosophila, silkworms, and
C. elegans, as well as the non-mammalian vertebrate zebrafish
(Jaramillo-Gutierrez et al., 2010; Wang et al., 2012, 2019;
Kobayashi et al., 2014; Sanada et al., 2014; Su et al., 2017; Xu
et al., 2020). A role for OXR1 in regulation of oxidative stress
response genes has been demonstrated in the mosquito, fruit
fly, zebrafish, and mammals (Jaramillo-Gutierrez et al., 2010;
Wang et al., 2012, 2019; Kobayashi et al., 2014; Yang et al.,
2014, 2015; Matsui et al., 2020; Xu et al., 2020). Thus, the
basic functions of OXR1 in oxidative stress resistance are highly
conserved in eukaryotes.
FIGURE 1 | Human OXR1 Isoforms. White boxes depict non-coding exons or
exon regions. The first coding exons of: OXR1A1 (Accession no.
NP_001185462.1) and OXR1A2 (Accession no. NP_060472.2) (red); OXR1B1
(Accession no. XP_016869078.1) and OXR1B2 (Accession no. NP_851999.2)
(gold); OXR1D1 (Accession no. NP_001185463) and OXR1D2 (Accession no.
NP_001185464.1) (yellow); variable exon 14 (green); TLDc Domain (dark
blue); exons shared by A and B forms (light blue) are highlighted.
OXR1 Gene Structure
Like many mammalian genes, human OXR1 expresses multiple
isoforms. Figure 1 shows the long (A and B) and short (D)
forms of human OXR1 (Elliott and Volkert, 2004; Oliver et al.,
2011; Yang et al., 2014). An additional human OXR1C form has
been found only in testes and has not been studied extensively
to date (Yang et al., 2014). These isoforms correspond to the
mRNA species identified in humans to date. The A forms appear
to be primarily brain specific forms (Elliott and Volkert, 2004;
Yang et al., 2014). In this review we have designated them A1
and A2, which differ only by the presence of the 81 bp exon
14 (A1), or its absence (A2). The A1 and A2 forms encode
proteins of 873 and 846 amino acids. The B forms are more
widely expressed and are typically found in cells of tissues
that have high levels of oxidative metabolic activity (Elliott and
Volkert, 2004; Yang et al., 2014; Finelli et al., 2016). As is the
case with the A forms, B1 and B2 differ by the presence or
absence of exon 14 and produce proteins of 866 and 839 amino
acids, respectively.
The short D forms are present in multiple tissues and
appear to be expressed from their own promoter (Finelli et al.,
2015). They begin with exon 13, which is not found in longer
forms of OXR1. The OXR1D forms (called Oxr1C in mouse)
are also produced with and without exon 14 (OXR1D1 and
OXR1D2, respectively) and produce proteins of 243 and 216
amino acids. All of the human A, B, C, and D isoforms contain
the C-terminal TLDc domain, a highly conserved domain of
unknown function (Durand et al., 2007; Finelli and Oliver,
2017). A recent review describes and compares the complete
family of proteins containing TLDc domains and their roles in
neurodegenerative diseases in detail (Finelli and Oliver, 2017).
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Studies of OXR1 often have not clearly distinguished the
specific isoforms, instead discriminating primarily between the
long and short forms. The A and B forms are typically described
as the long forms and the D forms (and the corresponding mouse
Oxr1C forms) are frequently called the short forms. Therefore,
potential differences beyond tissue specificity between the A, B,
C, and D forms of OXR1, or the roles of exons 13 and 14 are
not presently known. Although the mRNA of the A and B forms
are sufficiently different in length to allow their discrimination
on northern blots, the proteins produced from these mRNAs
are very similar in size making them difficult to distinguish by
Western blot analysis. Western blots using antibodies specific for
the OXR1 TLDc domain typically reveal proteins in mice that are
approximately 85, 55, 40, and 24 kDa (Oliver et al., 2011). While
the largest and the smallest forms are thought to correspond to
the OXR1B and D isoforms, the intermediates have not been
characterized to date. Whether these are truncated proteins, post-
translationally processed forms, or additional mouse-specific
splice variants is not clear.
OXR1 Homologs
A number of the TLDc family proteins are highly expressed
in neurons and many have been associated with neurological
defects and/or diseases (Finelli et al., 2016; Finelli and Oliver,
2017). The importance of the TLDc domain was demonstrated
in Drosophila by Wang et al. (2012), who found that the
phenotype resulting from deletion of the Drosophila OXR1
homolog mtd could be complemented by expression of isoforms
containing essentially just the TLDc domain (Wang et al.,
2012, 2019). Similarly, expression of either the long or short
forms of Oxr1 prevents neurodegeneration in Oxr1-deleted
Bella mouse (Oliver et al., 2011; Finelli et al., 2016). To
further test the importance of the TLDc domain, Finelli et al.
(2016) produced an insertion mutation in mice that deleted
the TLDc domain, which inactivated OXR1’s neuroprotective
functions. These results demonstrate that the TLDc domain
plays a critical role for OXR1 to function in neuroprotection,
however the mechanism of action remains elusive (for review see
Finelli and Oliver, 2017).
In this review, we focus primarily on the OXR1 gene and its
closest homolog, the nuclear coactivator 7 (NCOA7). Alignment
of the NCOA7 and OXR1B2 proteins reveals that 11 of the 16
exons are at least 40–70% identical in sequence (Durand et al.,
2007). The NCOA7 genomic structure also has a similar pattern
of size and spacing of exons and introns as OXR1 and produces
structurally similar long and short forms, suggesting that OXR1
and NCOA7 likely arose from gene duplication (Durand et al.,
2007; Shkolnik et al., 2008; Yu et al., 2014). The short form of
NCOA7 begins with a unique exon spliced to the TLDc domain
(Shkolnik et al., 2008; Yu et al., 2014). However, the amino acid
sequences of the unique first exons of the short forms of OXR1
and NCOA7 proteins do not share any homology. The short
form of NCOA7 is transcribed from its own promoter, which is
predicted to be the case for OXR1D as well (Yu et al., 2014; Finelli
et al., 2015). LikeOXR1,NCOA7 is highly expressed in most brain
neurons (Shao et al., 2002). Both OXR1 and NCOA7 contain the
highly conserved C-terminal TLDc domain.
OXR1 Induction
OXR1 is induced by oxidative stress, but the mechanism that
regulates this induction remains unclear. Increasing OXR1 levels
by the introduction of an additional copy of OXR1 transcribed
from a strong promoter increases cellular resistance to oxidative
stress, suggesting elevated OXR1 levels are critical for this
function (Finelli et al., 2016). In N2a mouse neuroblastoma cells
in culture, both the long and short forms of OXR1 are induced
by oxidative stress treatment, however, the timing of induction
of these isoforms is different. The long forms are induced within
30 min after treatment with an oxidative agent, whereas the
short forms are induced only after 2 h, suggesting they may be
independently regulated, respond to different levels of oxidative
stress, or are required at different stages of stress mitigation
(Finelli et al., 2015). Neither the short nor the long forms of
NCOA7 are induced by hydrogen peroxide (Durand et al., 2007;
Yu et al., 2014), but the long form is induced by arsenite treatment
(Finelli et al., 2016), suggesting that the NCOA7 response to
oxidative stress differs from that of OXR1, which responds to
treatment by both oxidative agents.
The importance of elevated levels of OXR1 to disease outcome
was demonstrated in a study by Liu et al. of the SOD1G93A
mouse model of ALS (Liu et al., 2015). This mouse, like humans
with ALS (Oliver et al., 2011), expresses OXR1 at elevated
levels, suggesting they have induced the OXR1 response and are
undergoing oxidative stress. Liu et al. constructed and tested a
mouse that carries both the SOD1G93A allele and a transgene
expressing Oxr1 from a strong neuron-specific promoter. In this
mouse the onset of disease was delayed, and its lifespan was
increased. This suggests that elevating OXR1 protein to levels
higher than the those normally attained when the endogenous
OXR1 gene is induced provides further protection from
neurodegeneration (Liu et al., 2015). In humans the importance
of the level of OXR1 is underscored by the recent study by
Chen et al. in which patients carrying a heterozygous OXR1
mutation that prevents expression of one copy of the OXR1D
isoform were found to have an impairment in the development
of language skills, suggesting that haploinsufficiency of only this
isoform results in a detectable neurological impairment which is
less severe when compared to the phenotype of patients that lack
expression of all OXR1 isoforms (Chen et al., 2017; Wang et al.,
2019). Therefore, a key to understanding OXR1 function is to
determine how OXR1 expression is regulated. Are there upstream
regulatory factors that are required, or does OXR1 function in an
autoregulatory pathway in response to oxidative stress?
OXR1 IS REQUIRED FOR NEURON
VIABILITY
OXR1 Is Required for Granular Cell Layer
Neuron Viability in the Cerebellum
The high-level expression of OXR1 in the brain, specifically
in neurons together with its role in reducing oxidative stress
sensitivity, led to the suggestion that OXR1 may play a
role in mitigating oxidative stress-induced neurodegeneration
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(Elliott and Volkert, 2004; Durand et al., 2007; Oliver et al., 2011).
The role of OXR1 in neurodegeneration was firmly established by
the discovery of the Bella mouse. Oliver et al. (2011) identified
this mouse model from a screen for movement disorders and
ataxia in mutagenized mice. The Bella mouse exhibited a rapidly
progressing ataxia that began at approximately 2 weeks of
age, resulting in severe ataxia and death by 4 weeks of age.
Although the mouse carried a deletion of two genes including
Oxr1, reintroduction of Oxr1 complemented the phenotype and
reversed the effects of the deletion, restoring the Bella mouse to
health and demonstrating that the pathology was due to loss of
Oxr1 (Oliver et al., 2011). Construction of a mouse in which the
C-terminal region of Oxr1 was deleted resulted in a phenotype
identical to that of the Bellamouse and confirmed the role ofOxr1
and the importance of the TLDc domain in reducing oxidative
stress and preventing neurodegeneration (Finelli et al., 2016).
The ataxia of the Bella mouse appears to result from oxidative
stress-induced degeneration of the granule cell layer (GCL)
neurons of the cerebellum that are involved in motor control
(Hashimoto et al., 1999; Ohgoh et al., 2000; Oliver et al., 2011;
Yamashita et al., 2011; Bodranghien et al., 2016). The time of
onset of the phenotype coincides with the approximate time that
these neurons are thought to stop dividing in mice, complete their
migration to their final location, and become mature, terminally
differentiated neurons (Ding et al., 2013; Leto et al., 2016). It is
at this time that the GCL neurons accumulate oxidative damage
and begin to die possibly because of their high levels of oxidative
metabolism and low levels of antioxidant enzymes (for review see
DiMauro and Schon, 2008; Watts et al., 2018).
It is unclear why only the cerebellar GCL neurons are
particularly vulnerable to oxidative stress and neurodegeneration
since most brain neurons express OXR1 at high levels. The early
death of the Bella mouse may prevent detection of damage to
other neurons possibly because they have lower levels of ROS
or higher levels of other protective proteins compensating for
the loss of OXR1. One possible explanation for the sensitivity of
the GCL neurons comes from the observation that their NCOA7
protein levels are relatively low compared to other brain neurons
(Protein Atlas1; Finelli et al., 2016). The high degree of homology
between NCOA7 and OXR1 raises the possibility that NCOA7
may compensate, at least to some extent, for the loss of OXR1
function by providing some protection from oxidative stress in
neurons where it is more highly expressed than in GCL neurons.
The ability of NCOA7 to complement OXR1 is further supported
by the results of Wang et al. (2019). They tested the ability of
human OXR1 and NCOA7 to complement the phenotype of
Drosophila carrying a deletion of the mustard (mtd) gene, the fly
homolog of OXR1. Most mtd mutant flies die at or before the
eclosion stage (emergence from the pupae). The few flies that
do emerge from their pupae die shortly thereafter. The short
forms of human OXR1 and NCOA7 were capable of restoring
viability to the mtd mutant flies demonstrating that only the
TLDc domain was necessary. This further supports the notion
that these two human genes have overlapping functions. This
needs to be tested by simultaneously modulating NCOA7 and
1https://www.proteinatlas.org
OXR1 expression in mammalian cells and testing oxidative stress
resistance levels.
OXR1 Is Required for Retinal Neuron
Viability
In addition to its role in protection of brain neurons, OXR1
appears to play a key role in several neurodegenerative diseases
of the retina. The first study demonstrating a role for OXR1 in
retinal degeneration used C57bl6/J mice. These mice develop
blindness when raised in high (75%) oxygen levels and have
been used as models for retinopathy of prematurity (Natoli
et al., 2008a,b), which can occur in preterm infants that require
supplemental oxygen for survival (for review see Hellstrom
et al., 2013). C57bl6/J sensitive mice and the Balb/c resistant
control mice used in this study induce OXR1 mRNA and
protein to high levels upon exposure to high oxygen and their
OXR1 mRNA and protein levels remain high during the period
when the photoreceptors are resistant to hyperoxia. However,
by approximately 14 days, OXR1 mRNA and protein levels are
reduced in the C57bl6/J mutant mouse to levels below those
measured prior to oxygen exposure and retinal degeneration
ensues. In the Balb/c control mice, OXR1 levels remain high and
no retinal changes are detectable. While this observation was
primarily correlational, it does suggest that OXR1 levels play a
role in the protection of photoreceptors from hyperoxia-induced
death (Natoli et al., 2008a).
A subsequent study of diabetic retinopathy more clearly
demonstrates a causal effect of OXR1 in retinal degeneration.
Murray et al. (2013) studied microRNA expression in the
Akita mouse model of diabetic retinopathy and found that the
microRNA miR-200b was induced shortly before the onset of
retinopathy. miR-200b destabilized OXR1 mRNA and reduced
expression of the protein. As the OXR1 mRNA and protein levels
declined, the retinal neurons accumulated an excess of oxidative
DNA damage resulting in the initiation of apoptosis and retinal
neuron death. Like most microRNAs, miR-200b destabilizes its
target mRNAs resulting in reduced levels of multiple mRNAs
and proteins. To determine if OXR1 was a key factor leading to
the oxidative damage and apoptosis, Murray et al. mimicked the
phenotype by introducing miR-200b to cultured retinal Muller
cells. This caused a rapid accumulation of oxidative damage and
increased apoptosis similar to that seen in the retina of the Akita
mouse. Introducing a miR-200b resistant form of OXR1 along
with the miR-200b to the Muller cells caused a reduction the level
of oxidative damage and apoptosis. This demonstrates that OXR1
expression confers resistance and enhances viability and that its
depletion is a major cause of cell death.
Depletion of OXR1 Affects
Neurodegeneration, and Cell Death
Two studies examined gene expression in several different brain
regions of post-mortem samples from Parkinson’s patients and
compared these with age matched controls. In all cell types
OXR1 mRNA levels were lower in the Parkinson’s groups
compared to matched controls (Zhang et al., 2005; Stamper
et al., 2008). These were most significant in the Broadman’s area
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9 neurons where OXR1 was 5.3-fold lower in the Parkinson’s
patients and in the posterior cingulate cortex pyramidal neurons
where the Parkinson’s patients without dementia exhibited a
3.0-fold reduction in OXR1 mRNA and those with dementia
showed a 2.0-fold reduction. Other brain regions showed minor
reductions in OXR1 levels of 1.7-fold (substantia nigra) and
1.4-fold (putamen).
The mechanism of OXR1 reduction in Parkinson’s was studied
by Li et al. (2017). They demonstrated that an increased level of
the OXR1-targeting microRNA miR-137 is found in exosomes
in serum of Parkinson’s patients compared to controls. Their
subsequent study demonstrated that exosomes can transport
miR-137 into brain neurons (Jiang et al., 2019). Exosomes
containing miR-137 are also found in the bloodstream of
mice treated with methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), a chemical that produces a Parkinson’s-like disease in
these animals as well as in humans (for review see Langston,
2017). The MPTP-treated mice had higher levels of oxidative
damage and apoptosis in their brain tissue along with a loss
of Nissl bodies in the neurons of the substantia nigra. MPTP-
treated mice showed increased tremors, decreased pole climbing
ability and decreased traction time when compared to control
mice. These MPTP-induced cellular changes and Parkinson’s-
like symptoms could be reversed by injection of a lentivirus that
over expressed OXR1 into the brain, strongly suggesting that the
pathological effects of miR-137 are due to its inhibition of OXR1
(Jiang et al., 2019).
A study by Mo et al. (2019) demonstrated that OXR1
repression increases the pathological consequences of ischemia
in a rat model. For reasons that are unclear, ischemia causes
the induction of the microRNA miR-365 which, like miR-137
and miR-200b, down regulates OXR1. The key experiments
demonstrated that miR-365 is induced upon occlusion of the
middle cerebral artery and that this microRNA represses the
expression of OXR1. Mo et al. then demonstrated that an
antagomir that blocks the ability of miR-365 to repress gene
expression restored OXR1 levels and reduced the extent of
the oxidative damage as measured in brain tissue by (γH2-
AX levels, a marker of DNA damage. Measurement of the
infarct zone showed that the extent of brain damage was also
reduced. Mo et al. (2019) concluded that the effects of miR-
365 were specifically due to repression of OXR1 expression
by adding an OXR1 specific siRNA along with the antagomir.
When OXR1 expression is repressed by the siRNA, the
antagomir was no longer able to provide protection indicating
that OXR1 expression is required to reduce brain damage
resulting from ischemia.
Two additional studies provide further support for a key
role for OXR1 in neurotoxicity and cell death. Sevoflurane is a
common anesthetic that has been associated with neurotoxicity in
rodents and humans (Bahmad et al., 2020; Sun, 2010). In human
hippocampal cells in culture, sevoflurane induces miR-302e, yet
another microRNA that represses OXR1 mRNA and protein
levels. Sevoflurane treatment increases levels of oxidative damage
and cell death. However, experimentally increasing OXR1 levels
abolished the ROS-associated toxicity of sevoflurane (Yang
et al., 2018). Piperlongumine functions by a completely different
mechanism. It is a compound that kills senescent cells because
of their elevated permeability to this drug. Piperlongumine
binds directly to the OXR1 protein, destabilizes it, and targets
it for degradation. In all of the above disease and cell death
models, once OXR1 protein levels decline, oxidative stress ensues,
triggering apoptosis and cell death (Zhang et al., 2018).
OXR1 Is Critical for Oxidative Stress
Resistance of Neurons
The above studies demonstrate that OXR1 expression is critical
for the survival of neurons experiencing oxidative stress. In
fact, when OXR1 is completely absent, as is the case in OXR1-
deleted mice, the GCL neurons of the cerebellum cannot
survive once they become mature neurons, possibly because
of their high levels of oxidative metabolism and low levels of
antioxidant enzymes (DiMauro and Schon, 2008; Oliver et al.,
2011; Watts et al., 2018). A reduction in OXR1 levels, either
by elevated expression of a number of different microRNAs or
by destabilization of the protein, increases cellular sensitivity to
oxidative stress, apoptosis, and cell death. In animal models this
leads to neurodegeneration.
In humans, mutations that cause bi-allelic loss of function
and absence of OXR1 expression result in a severe neurological
phenotype that manifests itself as developmental delay,
intellectual disability, language delay, cerebellar atrophy and
seizures. This suggests that in humans OXR1 plays a role during
development that results in neurological defects (Wang et al.,
2019). Human patients from a family that carried the same
heterozygous early termination mutation in the unique first exon
of OXR1D have been identified. These patients have language
impairments, suggesting haploinsufficiency of this form of
OXR1 leads to a neurological phenotype (Chen et al., 2017).
Developmental defects have also been noted in zebrafish and
Drosophila OXR1 mutants (Wang et al., 2012, 2019; Xu et al.,
2020). It is not clear if the developmental defects are due to role
of OXR1 in oxidative stress resistance, or if OXR1 has additional
functions required for normal neurological development.
To more fully understand the role of OXR1 in
neurodegenerative diseases much remains to be learned
about how OXR1 functions at the cellular and molecular level.
The information that is available does lead to a speculative model
of how OXR1 may function to protect cells from oxidative stress
induced death given the roles it plays in gene expression and
function which will be discussed below.
MOLECULAR AND CELLULAR BIOLOGY
OF OXR1
How Does OXR1 Function at the
Molecular and Cellular Level?
Although the specific molecular actions of the OXR1 isoforms
are not completely understood, three very important and
complementary mechanisms are beginning to emerge. These
include its role in controlling expression of oxidative stress
resistance genes by acting on the regulatory elements that are
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required for their induction or repression, the possibility that it
acts as a cellular sensor of oxidative stress, and its protein-protein
interactions that directly affect the function of OXR1’s interacting
partner proteins.
OXR1-Dependent Regulation of Gene
Expression
A variety of studies show that OXR1 has a regulatory role that
is involved in the control of a number of stress response genes
associated with survival during oxidative stress. A role for OXR1
in the regulation of gene expression was first demonstrated in
mosquitoes by Jaramillo-Gutierrez et al. (2010). A deletion of
OXR1 sensitized mosquitoes to H2O2 in their drinking water.
This phenotype was associated with an inability to induce a set
of genes, including glutathione peroxidase (GPX) and catalase,
both required for oxidative stress resistance. A regulatory role was
also suggested by the results of Oliver and coworkers who found
that the failing GCL neurons of the Bella mouse had about a
70% reduction in the level of GPX1, an ROS-detoxifying enzyme
(Oliver et al., 2011).
A regulatory function for OXR1 in mammalian cells was
directly demonstrated by two recent studies (Yang et al., 2014,
2015; Matsui et al., 2020). These studies showed that suppression
of OXR1 by an siRNA in HeLa cells caused sensitivity to
oxidative stress, reduced expression of the cyclin-dependent
kinase (p21/CIP1/WAF1), GPX2, and heme oxygenase (HO-
1/HMOX1), and abbreviated the G2/M checkpoint arrest, either
after peroxide treatment, or gamma irradiation (Yang et al., 2014,
2015; Matsui et al., 2020). Yang et al. (2015) demonstrated that
OXR1 functions upstream of regulatory proteins such as HIF1A,
SP6, E2F8, TCF3, p21, Fos, and Jun, that control a variety of
stress responses. The nuclear factor erythroid 2-related factor 2
(Nrf2) is known to regulate a number of oxidative stress genes (for
review see Tonelli et al., 2018; He et al., 2020), including GPX2
and HMOX1. Both of these genes are no longer inducible when
OXR1 is depleted, suggesting that OXR1 may also be required
for the induction of Nrf2-dependent oxidative stress resistance
gene expression (Bryan et al., 2013; Xiong et al., 2015). A role for
OXR1 in Nrf2-dependent regulation is further supported by the
observation that OXR1 interacts directly with the Keap1 protein,
which regulates Nrf2 activity (Yang et al., 2020).
Among the genes that are differentially expressed in an OXR1-
depleted HeLa cell line are those that metabolize or detoxify
ROS, genes that affect apoptosis, genes involved in autophagy,
and genes of the p53 response that control the cell cycle during
oxidative stress. OXR1 enhances DNA repair, cell cycle arrest,
ROS detoxification, and other resistance mechanisms, while
repressing apoptosis (Yang et al., 2015). Thus, OXR1 functions
to activate a multifaceted response to oxidative stress, apparently
by controlling multiple transcriptional regulators that in turn
function to control the expression of genes that increase oxidative
stress resistance and cell viability.
A recent study by Yang et al. (2020) provides further insights
into OXR1’s regulatory mechanism. This study shows that in
human U2OS osteosarcoma cells and rat GH3 pituitary tumor
cells, OXR1 interacts with protein methyl transferase 5 (PRMT5)
and stimulates its activity after peroxide treatment. PRMT5
methylates arginine residues within histones H3 and H4 to
modulate chromatin structure, a key step in transcriptional
activation of genes (Lorton and Shechter, 2019). Their conclusion
that the OXR1A isoform is a coactivator of PRMT5 raises the
possibility that OXR1 may affect gene expression by modulating
histone methylation and chromatin structure. Both OXR1 and
PRMT5 affect transcription both positively and negatively (Blanc
and Richard, 2017; Yang et al., 2020). OXR1 was also shown
to stimulate PRMT5-dependent methylation of p53, which
results in cell cycle arrest. p53 also controls genes involved
in DNA repair and apoptosis, increasing repair and repressing
apoptosis (Berger, 2008; Jansson et al., 2008). This raises the
possibility that the repression of the cell cycle and inhibition of
apoptosis upon oxidative damage, which requires OXR1, may
be mediated through its interaction with PRMT5 and p53 (Yang
et al., 2015, 2020). OXR1 protein interacts with PRMT5 in
both the cytoplasm and nucleus, potentially implicating it in
stimulating the methylation of both cytoplasmic and nuclear
proteins including histones (Yang et al., 2020).
In addition to interacting with PRMT5, OXR1 was also shown
to interact with PRMT1. Therefore, OXR1 may function to
modulate the activity of multiple protein methylases and other
regulatory proteins (Finelli et al., 2015; Yang et al., 2020). Thus,
the ability of OXR1 to regulate gene expression may result
from its protein-protein interactions with PRMT5 potentially
remodeling chromatin structure to stimulate gene expression
and/or directly stimulate regulatory proteins to carry out their
functions. The interaction of OXR1 with PRMT proteins appears
to function via the TLDc domain, since OXR1D protein also
binds to PRMT5, suggesting this interaction may be shared by
all OXR1 isoforms and possibly other TLDc domain proteins.
ROS Sensing
The function of OXR1 upstream of a number of regulatory
elements led to the suggestion that it may act as a global sensor
of oxidative stress in cells (Yang et al., 2015). This hypothesis
is intriguing, but evidence for a mechanism of action remains
to be determined. The sensor hypothesis implies that OXR1
must be able to assess some feature of oxidative stress and then
signal through its downstream targets that the stress level has
become sufficiently severe to trigger the induction of the OXR1-
dependent response.
OXR1 has two activities that could potentially function as
cellular sensors of oxidative stress. One biochemically defined
potential sensing mechanism involves a highly conserved
cysteine residue, which is Cys753 in the mouse Oxr1 gene. This
cysteine is found in the TLDc domain of both OXR1 and
NCOA7 and is present in OXR1 of a large number of species
including human, mouse, and Drosophila (Oliver et al., 2011;
Finelli et al., 2016). It is oxidized by H2O2, but its reactivity is too
weak to provide OXR1 with an antioxidant activity sufficiently
strong enough to function as an antioxidant protein (Oliver
et al., 2011). However, the weak ROS-interacting mechanism of
Cys753 could function well as a sensing mechanism that leads
to activation of OXR1 only when ROS reaches a critical level
that is sufficiently strong to oxidize Cys753. Several oxidative
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stress-associated proteins, including DJ-1 and MTK-1, have
redox-sensitive cysteine residues that are responsive to ROS
levels and which have been shown to modulate the downstream
regulatory and catalytic properties of these proteins (Wilson,
2011; Hijioka et al., 2017; Matsushita et al., 2020). Similar
biochemical investigations, along with site-directed mutagenesis
of Cys753 and its potential effects on OXR1-dependent gene
expression, have yet to be performed.
The OXR1 protein can reduce oxidative damage when
expressed at high levels in E. coli (Murphy and Volkert, 2012)
reducing the oxidative damage to DNA that results from low-
level, spontaneous ROS production. This suggests a second
possible sensing mechanism. The active region required for
this activity was localized to a domain within exon 11 that is
highly conserved among OXR1 homologs in other species and
in the NCOA7 gene and its homologs. It is unclear how this
domain functions at the molecular and biochemical level, but
it was demonstrated that this region of OXR1 can reduce the
DNA damage resulting from ROS (Murphy and Volkert, 2012),
suggesting it may interact directly with ROS, or affect the function
of ROS production or detoxification proteins.
It is possible that both regions of OXR1 protein react with
ROS directly and function together in cellular sensing. The
exon 11 domain may act as an oxidative stress sensing region
in the longer isoforms of OXR1. The low reactivity of Cys753
raises the possibility that this site may respond only when
ROS reach a critical level. It is also the only potential sensing
mechanism present in the short forms of OXR1. Determining if
these domains function in ROS signaling and OXR1 activation
requires further study.
Subcellular Localization of OXR1 Protein
Examination of the dynamics of OXR1 localization provides
insights into how it might function. Initial localization studies
showed that OXR1 is present in the mitochondria of yeast and
mammalian cells (Elliott and Volkert, 2004). Mitochondria carry
out oxidative phosphorylation for cellular energy production,
a process that is the major source of intracellular ROS.
Mitochondrial localization of OXR1 led to the suggestion that
it may protect cells by its presence in this organelle (Elliott
and Volkert, 2004). When an intermediate sized isoform of the
human OXR1 protein was tested for its ability to restore peroxide
resistance to a yeast OXR1 deletion mutant, it was able to do
so only if it entered the mitochondria. This demonstrates that
mitochondrial localization is required in yeast cells for oxidative
stress resistance (Elliott and Volkert, 2004). In mammalian cells,
the short isoform was shown to localize to the outer membrane
of the mitochondria (Wu et al., 2016). Unlike yeast, however,
oxidative stress resistance was best achieved in mammalian
cells in which OXR1 was overexpressed and localized to the
cytoplasm rather than the mitochondria. It was observed that the
cytoplasmic short form can prevent the morphological changes in
mitochondria that result from rotenone-induced oxidative stress
(Wu et al., 2016).
OXR1 silencing studies in HeLa cells showed that depletion of
OXR1 by inhibitory RNA (RNAi) caused cellular levels of ROS
to rise, which caused mitochondrial DNA damage and initiated
a cycle of increased production of ROS by the mitochondria
and further cellular damage (Yang et al., 2014). As ROS levels
rose, mitochondria became unstable and apoptosis was induced
(Yang et al., 2014; Wu et al., 2016). The importance of OXR1
for mitochondrial stability and ROS control was underscored
by the result that OXR1 depletion by RNAi methods had no
effect on peroxide-induced oxidative stress resistance in cells
lacking mitochondrial DNA (Yang et al., 2014). The large number
of changes resulting from OXR1 depletion demonstrates that
OXR1 is required for the expression of many genes that protect
cells from oxidative stress and the repression of proapoptotic
genes (Yang et al., 2014, 2015). Thus, it appears that OXR1
controls mitochondrial resistance to oxidative stress by regulating
oxidative stress responsive genes (Yang et al., 2014).
Localization and migration of OXR1 in response to oxidative
stress was examined in the rod photoreceptor cells of C57bl6/J
mice, previously described as a model of oxygen-induced retinal
degeneration (Natoli et al., 2008a). OXR1 localizes to the inner
portion of the outer segments of the photoreceptors prior to
the onset of retinal degeneration. Photoreceptor outer segments
lack mitochondria indicating a cytoplasmic localization of OXR1
in non-stressed cells (Natoli et al., 2008a; Figure 2). The outer
segments contain the photoactive pigments needed for light
perception in layers of disks. Extensive photo-oxidation reactions
occur in the outer segments and ROS levels are high, especially
when the eye is exposed to light of shorter wave lengths
(Roehlecke et al., 2013). All protein synthesis occurs in the inner
segment of the photoreceptor cell. A transition zone links the
inner and outer segments and all cellular components synthesized
in the inner segment that are required for outer segment’s
visual functions must be transported through the transition
zone. As described previously, incubation of C57bl6/J mice in
high oxygen triggers neurodegeneration of the photoreceptor
cells. As their degeneration progresses, OXR1 protein migrates
from the outer segment back into the inner segment, passing
through the transition zone and entering the nucleus (Natoli
et al., 2008a; Figure 2). Nuclear localization is consistent with
the known regulatory effects of OXR1 on gene expression during
oxidative stress (Yang et al., 2014, 2015). While localization to
outer segments is unique to photoreceptor cells, its presence in
the nucleus of HeLa cells was described by Yang et al. (2020).
The localization of OXR1 in the outer segments of non-stressed
photoreceptor cells may be associated with the high levels of
ROS present and the photo-oxidation that occurs in this region
of the cell. It is not known which isoform(s) of OXR1 showed
this localization pattern because the antibody used in this study
recognized the TLDc domain and therefore detects all major
isoforms of OXR1.
OXR1 localizes to two highly oxidizing cellular compartments,
the outer segments of photoreceptor cells and the mitochondria
of other cells (Elliott and Volkert, 2004; Natoli et al., 2008a; Yang
et al., 2014; Wu et al., 2016). OXR1 also is found in the cytoplasm,
however, its function in this compartment still requires normal
mitochondrial activity, since cells lacking mitochondrial DNA,
which inhibits mitochondrial function, are not sensitized to
peroxide treatment upon depletion of OXR1 (Yang et al., 2014).
This suggests OXR1 is monitoring mitochondrial oxidative stress
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FIGURE 2 | Localization and Migration of OXR1 Upon Oxidative Stress. A
typical rod photoreceptor is shown. Rods comprise the majority of
photoreceptors in mammals (approximately 98% in mice and 95% in
humans). OXR1 is initially located in the inner portion of the outer segment of
mouse photoreceptors. Oxidative stress causes OXR1 migration from the
outer segment, through transition zone (TZ), into the inner segment and the
nucleus (Natoli et al., 2008a). Photo-oxidation of rhodopsin contained within
the membrane disks initiates a cascade of chemical reactions that convert
light signals into electrical signals transmitted by the photoreceptors to the
brain via intermediary neurons. OXR1 localization in the outer segment may
serve to monitor ROS levels and trigger a genetic response when ROS level
are sufficient to cause stress. Basal body (BB), endoplasmic reticulum (ER).
while present in the cytoplasm, possibly responding to a signal
released from mitochondria upon stress.
Combining these studies suggests that OXR1 functions to
monitor oxidative stress levels in highly oxidizing compartments
of cells. in photoreceptor cells it is monitoring the highly
oxidizing environment of the outer segment. In other cell types,
OXR1 is monitoring oxidative stress levels, either by its presence
in mitochondria, or by monitoring release of mitochondrial
oxidative stress signals into the cytoplasm. Moreover, the
mitochondrial localized short forms may monitor oxidative
stress within the mitochondria, while the cytoplasmic long
forms monitor mitochondrial stress levels via signals released
into the cytoplasm.
Direct Protein-Protein Interactions
Contribute to the Role of OXR1 in
Neurodegeneration
A third molecular function for OXR1 has been demonstrated
in a series of papers from the lab of Peter Oliver (Finelli et al.,
2019; Svistunova et al., 2019; Williamson et al., 2019). This
group has shown that OXR1 interacts directly with a number
of proteins including proteins involved in ROS production and
detoxification. OXR1 also appears to have additional protein-
protein interactions that may contribute to the delay of disease
onset and death in the ALS mouse model carrying TDP-43
mutations. Finelli et al. (2015) first showed that OXR1D (Oxr1C
in mouse) binds to wild type TDP-43 and FUS proteins, two
ALS associated proteins. TDP-43 is a protein involved in multiple
mRNA production and processing steps (Buratti and Baralle,
2008). The mutant TDP-43M337V protein is associated with ALS
and accumulates in cytoplasmic stress granules. Raising the levels
of OXR1 protein in cells over expressing the TDP-43M337V allele
increases localization of TDP-43M337V protein in the nucleus
and decreases localization of TDP-43M337V in stress granules.
The M337V mutation of TDP-43 results in aberrant splicing of
the RNA of the Mtfr-1 (mitochondrial fission receptor-1) gene.
To determine if increasing OXR1 levels and improving nuclear
localization of TDP-43 restored normal TDP-43 function, Mtrf-1
splicing was examined. The RNA of this gene was again spliced
normally indicating that increasing OXR1 protein levels restores
TDP-43’s nuclear localization and its splicing function (Finelli
et al., 2015; Williamson et al., 2019).
Next, Williamson et al. (2019) tested the ability of OXR1 over
expression to alleviate the symptoms of ALS in a mouse that
carries the human M337V mutant TDP-43 as a transgene. As
is the case in cell lines with this mutation, the mutant human
TDP-43M337V protein localizes to stress granules in primary
neurons from this mouse. Crossing this TDP-43M337V mouse
with a mouse that over expresses Oxr1 in neurons yielded
primary neurons with increased TDP-43M337V localization in
the neuronal nuclei. The TDP-43MV337V mouse that over
expresses OXR1 from the transgene had decreased muscle
denervation, decreased neuromuscular degeneration, decreased
neuroinflammation and improved motor function. At present it
is unclear if the reduction in ROS levels seen when OXR1 levels
were increased (Finelli et al., 2016), the improved localization of
TDP-43m337V seen in cells (Finelli et al., 2015), or possibly both
of these consequences of OXR1 overexpression contribute to the
suppression of the phenotype of the TDP-43M337V mouse.
Protein-Protein Interactions May
Modulate ROS Levels
The Oliver lab has also provided compelling evidence that OXR1
regulates the function of the key metabolic enzyme glucose-
6-phosphate isomerase (GPI) through direct protein-protein
interactions (Finelli et al., 2019). The human brain consumes
large amounts of glucose through oxidative catabolism and
disruption of normal glucose metabolism is a feature of several
neurodegenerative diseases (Mergenthaler et al., 2013). OXR1
deletion mutant mice showed significant neurodegeneration that
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was preceded by an inability to down regulate glycolytic activity
under oxidative stress. They also showed a disruption in the
levels of many metabolites produced downstream of glucose-
6-phosphate during its metabolism. Glucose-6-phosphate is an
early intermediate in glycolysis and the pentose phosphate
pathway, two pathways associated with ROS production. Both
pathways are impacted by the activity of GPI, a key enzyme
in the early stages of glucose metabolism. The investigators
demonstrated that OXR1 physically interacts with GPI through
its TLDc domain and that this interaction modulates the
neuroprotective and cytokine activities of GPI through its level of
oligomerization. OXR1 binding to GPI reduces multimeric forms
associated with GPI’s glycolytic activity in favor of monomeric
forms responsible for GPI’s cytokine activity, a shift that was
shown to decrease in OXR1 mutants.
Like GPI, peroxiredoxin 2 (Prdx2) is a multifunctional
protein. It has a powerful antioxidant activity and the ability
to act as a molecular chaperone. These activities, along with
its high level of expression in neurons, make it an important
target for studies of neurodegeneration, which is consistently
associated with aberrant levels of oxidative stress and protein
aggregation. Svistunova et al. (2019) showed that OXR1 binds
to Prdx2 and modulates its activities. This study provided
evidence that OXR1 acts as a functional switch for Prdx2 in the
cerebellum, fine-tuning its activity by modulating both its degree
of oligomerization and two key post-translational modifications,
S-nitrosylation and overoxidation. In OXR1 knockout mice,
S-nitrosylation of Prdx2 was high while overoxidation was
low, a combination that inhibits Prdx2-associated antioxidant
activity and may result in high ROS in cells and subsequent
neurodegeneration. As expected, increased expression of OXR1
reversed these modifications.
OXR1 and the Immune Response
Liu et al. (2015) found that, in addition to affecting the expression
of oxidative stress resistance genes, the elevated immune response
is rescued by Oxr1 over expression in mouse models of ALS.
They find that neuronal over expression ofOxr1 in the SOD1G93A
mutant reduced expression of several markers of macrophage
activation and microgliosis that were induced in SOD1G93A
mouse. STAT3 phosphorylation and its subsequent activation
of downstream immune responses occurs in the SOD1G93A
mice but are reduced when Oxr1 is over expressed in neurons.
Controlling neuroinflammation and the immune response can
further contribute to increased viability of neurons. It remains
to be determined if this is a direct regulatory effect of OXR1
expression or if OXR1-mediated repression of oxidative stress in
neurons reduces the need for activation of an immune response
(Staal et al., 1994; Reuter et al., 2010).
Hypothetical Model of the OXR1
Regulatory Cascade
Combining the various known roles of OXR1 in regulating
cellular responses to oxidative stress leads to a potential model
of how OXR1 may function in neurons, which is presented in
Figure 3. If the proposal that OXR1 is a sensor of oxidative
stress is correct (Yang et al., 2015), OXR1 proteins may sense
the levels of ROS in locations like the photoreceptor outer
segments and mitochondria (Elliott and Volkert, 2004; Yang
et al., 2014; Wu et al., 2016), possibly by the interaction of
ROS with the exon 11 domain (Murphy and Volkert, 2012),
by direct oxidation of Cys753 (Oliver et al., 2011), or both. In
Figure 3 we include both the possibility that mitochondrially-
associated OXR1D directly monitors mitochondrial stress and
that cytoplasmic OXR1 proteins may respond to signals released
by mitochondria as they become stressed. The possibility that
the signal sensed by OXR1 may be ROS, or another product or
products resulting from oxidative stress or ROS activity remains
to be determined.
Regardless of whether OXR1 acts directly as a sensor of
ROS or responds to an unknown product of ROS activity or
oxidative stress, it is clear that a stress response is stimulated
by OXR1 and that this results in prevention cell death by
altering gene expression and through direct protein-protein
interactions. OXR1 has been shown to interact with PRMT5 and
possibly PRMT1. These interactions may modulate transcription
of genes by altering chromatin structure (Yang et al., 2020).
This may be a key mechanism by which OXR1 acts to stimulate
transcription of oxidative stress resistance gene expression. There
are, however, several additional mechanisms by which OXR1
may control gene expression. Since PRMT proteins also modify
proteins other than histones (Lorton and Shechter, 2019), the
OXR1-PRMT interactions could stimulate gene expression by
activating regulatory proteins via methylation, as has been
demonstrated for p53 (Yang et al., 2020). OXR1 also binds
directly to a number of proteins besides the PRMTs, including
several transcriptional regulatory proteins (Finelli et al., 2015;
Yang et al., 2020). Therefore, it could also act independently
of PRMTs to directly stimulate regulatory proteins that control
expression of oxidative stress resistance genes. Both functions
are possible and OXR1 likely acts through PRMT-dependent
and PRMT-independent gene regulatory mechanisms. Its close
homolog NCOA7 functions as a nuclear coactivator that binds
to the estrogen receptor regulatory complex, which then binds to
and activates the promoters of specific genes (Shao et al., 2002).
A direct transcriptional coactivation role for OXR1 has not been
tested and remains a possibility.
Additionally, OXR1’s protein-protein interactions modulate
the activities of ROS production and detoxification proteins,
which may affect ROS levels, as well as other proteins involved
in neurodegeneration (Finelli et al., 2015, 2019; Svistunova
et al., 2019; Williamson et al., 2019; Yang et al., 2020). Thus,
OXR1 provides a direct protection from neurodegenerative
diseases in addition to its role in regulating gene expression.
While the consequences of OXR1’s interactions with TDP-43,
peroxiredoxin, and GPI proteins have been characterized and
shown to be protective (Finelli et al., 2015, 2019; Svistunova et al.,
2019; Williamson et al., 2019), the consequences of its interaction
with a number of other proteins are less well understood. The
underlying theme does, however, emerge that OXR1 is intimately
tied to controlling the cell’s response to oxidative stress and
neurodegeneration at several different levels. It causes changes
in gene expression that increase oxidative stress resistance and
promotes protein activities that protect cells from oxidative stress
and neurodegeneration.
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FIGURE 3 | OXR1-mediated Oxidative Stress Resistance Model. Based on our current understanding, OXR1 functions in multiple pathways that contribute to
oxidative stress resistance. In this model cells experience oxidative stress, either due to external or internal factors affecting ROS levels and respond in an
OXR1-dependent fashion. Mitochondria are required for OXR1 function (Yang et al., 2014) (upper left). When oxidative stress occurs, mitochondrial bound and/or
cytoplasmic OXR1 forms act as sensors that respond to the signal (possibly ROS) and triggers downstream protective pathways. Pathways shown with solid lines
are supported by multiple lines of evidence. Dashed lines represent hypothetical pathways. The red arrows indicate pathways involved in activation or repression of
gene expression. One set of red arrows illustrate direct protein-protein interactions of OXR1 with transcription factors to alter gene expression. A second red
pathway indicates regulation by OXR1 interaction with PRMT5, PRMT1 and possibly other PRMT proteins. PRMT proteins methylate histones and modulate
chromatin structure and proteins other than histones, possibly including transcription factors. Blue arrows depict the PRMT5 activation of p53 to arrest the cell cycle,
which is necessary for efficient DNA repair and regulation of apoptosis (Yang et al., 2020). Green arrows depict interactions of OXR1 with other proteins to modulate
their activities (Finelli et al., 2015, 2019; Svistunova et al., 2019; Williamson et al., 2019).
The role of OXR1 as a key player in oxidative stress
resistance and neurodegeneration is becoming clear, however
much remains to be learned about how oxidative stress is
sensed in the cell, what the sensing signal is, and how OXR1
functions to alter gene expression to confer resistance and
tolerance of oxidative stress. OXR1 also appears to interact
with other proteins that are not directly related to oxidative
stress but do play roles in neurodegenerative diseases. Figure 3
combines the various known and hypothetical functions of
OXR1 into a cohesive picture that includes its possible role as
a sensor, its interaction with various proteins, and the known
and hypothetical consequences of the various protein-protein
interactions described above. Current efforts to examine the
various mechanisms of action are underway and should greatly
aid our understanding of OXR1 functions.
THERAPEUTIC POTENTIAL OF OXR1
OXR1 Gene Therapy
Attempts to treat neurodegenerative diseases with antioxidants
have largely failed (Group, 1993; Lloret et al., 2009). One
possible explanation is that ROS are involved in many metabolic
pathways and functions as signaling molecules (D’Autreaux
and Toledano, 2007). Treatment with antioxidants is not
selective and may interfere with oxidative metabolism and
cellular signaling pathways that employ ROS in addition to
detoxifying deleterious ROS. Controlling ROS levels by activating
cellular oxidative stress resistance mechanisms may be more
selective, allowing normal oxidative metabolism and ROS
signaling to proceed while detoxifying and reducing levels of
harmful ROS.
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OXR1 gene therapy could treat multiple neurodegenerative
diseases, because oxidative stress is a common event that leads
to neuronal cell death (Sayre et al., 2008; van Horssen et al.,
2011; Punzo et al., 2012; Calderon et al., 2017; Liu et al., 2017;
Puspita et al., 2017; Angelova and Abramov, 2018; Lupoli et al.,
2018; Wu et al., 2018). Increasing OXR1 expression to higher
levels by introducing extra copies using an adeno-associated viral
(AAV) vector that expresses a microRNA resistant form of OXR1
could potentially be used to treat such diseases. This can be
beneficial, in cells that have repressed their normal OXR1 levels
by a miRNA or through protein destabilization. Since protection
from degeneration also occurs upon elevating OXR1 protein
levels further in cells where its expression is already high, OXR1
gene therapy can potentially also be beneficial in cells where it
is not repressed (Finelli et al., 2015; Liu et al., 2015; Williamson
et al., 2019). Moreover, high level expression of OXR1 in brain
neurons was not associated with any detectable pathological
consequences, suggesting elevating OXR1 levels is safe (Oliver
et al., 2011; Liu et al., 2015).
AAV-Nrf2 gene therapy has been tested in a mouse model
of retinal degeneration as a potential approach to treat multiple
retinal degenerative diseases by treating oxidative stress (Xiong
et al., 2015). Like OXR1, Nrf2 is a regulatory gene that controls
genes required for oxidative stress resistance. It has been used
to treat retinal degeneration in rd1 and rd10 mutant mice.
These mutations cause loss of vision within approximately 4 and
8 weeks, respectively. Introduction of Nrf2 into the retina of these
mice resulted in a retention of some visual activity in the rd10
mouse, as measured by electroretinography. Two oxidative stress
resistance genes regulated by Nrf2 are the GPX2 and HMOX1
genes. OXR1 is also required for the expression of these genes
and controls a wide array of additional genes that contribute to
resistance and viability.
Many current gene therapy approaches focus on identification
of a defective gene and introduction of a wild type copy to
restore function. Such therapies have a limited application. For
example, gene therapy for Leber’s congenital amaurosis (LCA),
a retinal degenerative disease, recently received FDA approval.
This treatment introduces a wild type copy of the RPE65 gene
(Cideciyan, 2010; Boye et al., 2015; Feuer et al., 2016; Weleber
et al., 2016). While this is the most common gene mutation that
causes LCA, there are at least 17 other mutant genes known to
cause this disease that this therapy cannot treat (Cideciyan, 2010;
Kumaran et al., 2017). Retinitis pigmentosa poses an even bigger
problem as over 50 different genes have been identified that cause
this retinal degenerative disease (Petit et al., 2016).
While gene therapy for retinal degenerative diseases is
currently achievable, the use of such therapies in the brain will
require the development of vectors capable of crossing the blood-
brain barrier, or the use of more invasive methods, such as
direct injection. Should it be possible to safely overcome these
issues, OXR1 gene therapy could treat multiple diseases in which
oxidative stress contributes to neurodegeneration.
In addition to adding extra copies of OXR1 using an AAV
vector, it is also possible to increase OXR1 gene expression by
other genetic and biochemical means. Genetic approaches, such
as that used by Mo et al. (2019) and described above, to block
the action of inhibitory microRNAs by introducing an antagomir,
can restore OXR1 expression in diseases where microRNAs play
a role. In such diseases it is potentially possible to use CRISPR
methods to alter the sequences of the OXR1 gene that encode
the microRNA targets of OXR1 mRNAs. CRISPR has recently
been used to increase transcription by altering the promoter
activity of genes (Liao et al., 2017; Moreno et al., 2018; Bohm
et al., 2020). Since increasing OXR1 expression is the goal of all
of these therapies, using CRISPR methods to genetically alter
the promoter function to increase transcription, or searching for
small molecules or other drugs that increase OXR1 protein levels
or stability are also possible strategies worthy of exploration.
CONCLUSION
The experiments that have been done in OXR1-deletion mutant
mice, ALS mouse models, the MPTP-treated Parkinson’s mice,
the ischemic rat model, and in mouse models of retinal
degenerative diseases underscore the important role that OXR1
plays in protecting neuronal cells from degeneration in multiple
diseases. It also demonstrates that neuronal protection results
from its role in oxidative stress resistance as well as its protein-
protein interactions and effects on neuroinflammation. These
studies strongly suggest that OXR1-mediated gene therapy
can protect neurons from degeneration in such diseases.
The Parkinson’s and ALS mouse models further demonstrate
that increasing OXR1 expression alleviates physical symptoms
associated with neurodegeneration (Liu et al., 2015; Li et al.,
2017; Jiang et al., 2019; Williamson et al., 2019). These studies
clearly make OXR1 an appealing therapeutic target for the
treatment of neurodegenerative diseases. Further studies of the
molecular and cellular mechanisms of OXR1 are needed to
better understand how it confers oxidative stress resistance to
cells. Such studies can reveal additional potential points of
therapeutic intervention to modulate the expression of oxidative
stress resistance genes for the treatment of neurodegenerative
diseases. Current genetic methods make such therapies a realistic
possibility in the near future.
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